Abstract P3-08-18: The AmeliaTM-1 study: A phase 1b/2 study assessing the safety and efficacy of evexomostat (SDX-7320) plus a PI3K/Akt inhibitor and fulvestrant in patients with advanced HR+/Her2- breast cancer
Peter Cornelius, David J. Browning, Benjamin A. Mayes, P Dufour et autres